Evercore and International Strategy & Investment Group merged together back in the fall of 2014 to create Evercore ISI, a highly regarded investment bank with a mission to "create and deliver the most useful investment research to [their] clients." Evercore ISI released an updated list of their healthcare stock ratings last night, and set an 'Outperform' rating for shares of AbbVie (NYSE:ABBV). Evercore's new price target for AbbVie is $95 per share. At the time of writing this, shares of ABBV were trading at $69.98 per share, representing a roughly 36% upside.
Related: Is AbbVie a Marijuana Stock?
Evercore's $95 price target is the highest of analyst price targets for AbbVie. The average analyst price target for ABBV is $75.45, with the median analyst price target being $73 according to the Wall Street Journal. Currently, the lowest analyst price target for shares of ABBV is $60.
Related: Analyst Upgrades Shares of ZYNE to a 'Buy'
For more cannabinoid biotech stocks, check out our biotech marijuana stock database. Be sure to subscribe to one or more of our free newsletters so you never miss an important marijuana stock update. Also, don't forget to connect with The Daily Marijuana Observer on social media via Facebook, Twitter, StockTwits, and Instagram.
D/M/O
